top of page

We are being heard!

Our response to the FDA’s request for public comments on REMS modifications, signed by nearly 1,600 members and supporters, received national attention in the July 25, 2023 edition of Regulatory Affairs Professionals Society:

REMS: Stakeholders seek flexibility in changing REMS vendors | RAPS

Our website, which is receiving dozens of new member requests each day, is cited by the Treatment Advocacy Center’s Research Weekly publication for August 2, 2023:

And on August 9, 2023, ten members of the U.S. House of Representatives sent a letter to the FDA seeking urgent reforms of the clozapine REMS program. The nuances and technicalities of the REMS’ barriers to clozapine treatment are difficult to explain and communicate. These government leaders, led by Representative Brad Sherman (D-CA), took the time to review, understand and support our cause:

Brad Sherman (D-CA)

Betty McCollum (D-MN)

Dan Kildee (D-MI)

Josh Gottheimer (D-NJ)

David Trone (D-MD)

Marcy Kaptur (D-OH)

David Schweikert (R-AZ)

Jill Tokuda (D-HI)

Debbie Lesko (R-AZ)

Mikie Sherrill (D-NJ)

Read their letter to FDA commissioner Dr. Robert Califf here:

Download PDF • 422KB

The effort towards publicizing and circulating this congressional ‘Dear Colleague’ letter was supported and sponsored by the Schizophrenia & Psychosis Action Alliance (S&PAA). This organization has tirelessly supported and inspired The Angry Moms since the very beginning of our grass roots advocacy effort.

Thank you to S&PAA and our thousands of members and supporters. We are being heard!

Now, will the FDA hear us?

bottom of page